SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH
LOE ApproachingNDAORALTABLET
Approved
May 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH by Fosun Pharma is clinical pharmacology sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. First approved in 1982.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sulfamethoxazole and trimethoprim double strength is a fixed-dose combination antibiotic that inhibits bacterial nucleic acid synthesis through sequential blocking of dihydrofolic acid and tetrahydrofolic acid production. It is used to treat bacterial infections including urinary tract infections, Pneumocystis jiroveci pneumonia, and traveler's diarrhea caused by susceptible gram-positive and gram-negative organisms. The synergistic mechanism results in slower resistance development compared to either agent alone.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30% intensity), indicating potential downsizing of brand teams and shift to generic support or line extensions.
Mechanism of Action
CLINICAL PHARMACOLOGY Sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. The metabolism of…
Worked on SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.